UBS Group
DRMA icon

UBS Group’s Dermata Therapeutics DRMA Stock Holding History

UBS Group’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.1K Buy
35,608
+34,371
+2,779% +$57.8K ﹤0.01% 7464
2025
Q4 		$2.87K Sell
1,237
-8,810
-88% -$28.8K ﹤0.01% 9201
2025
Q3 		$50.4K Buy
10,047
+951
+10% +$5.78K ﹤0.01% 7563
2025
Q2 		$53.2K Buy
9,096
+2,067
+29% +$15.9K ﹤0.01% 7716
2025
Q1 		$75.9K Buy
7,029
+5,642
+407% +$69.4K ﹤0.01% 7259
2024
Q4 		$18.7K Buy
1,387
+1,237
+825% +$16K ﹤0.01% 7921
2024
Q3 		$2.46K Sell
150
-21
-12% -$418 ﹤0.01% 8425
2024
Q2 		$4.08K Buy
+171
New +$7.44K ﹤0.01% 8131
2023
Q4 		– Sell
-1
Closed -$139 – 9415
2023
Q3 		$139 Sell
1
-46
-98% -$8.82K ﹤0.01% 8804
2023
Q2 		$11.6K Buy
47
+24
+104% +$6.55K ﹤0.01% 7102
2023
Q1 		$4.44K Buy
23
+7
+44% +$4.08K ﹤0.01% 8189
2022
Q4 		$15.3K Buy
16
+10
+167% +$12.5K ﹤0.01% 7995
2022
Q3 		$8K Buy
6
+1
+20% +$1.56K ﹤0.01% 8699
2022
Q2 		$7K Buy
5
+3
+150% +$6.18K ﹤0.01% 8470
2022
Q1 		$5K Buy
+2
New +$6.83K ﹤0.01% 9108
2021
Q4 		– Hold
0
– -$1K – 10338
2021
Q3 		– Hold
0
– – – 9168

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group's DRMA Position: Q1 2026 in Review

UBS Group increased its Dermata Therapeutics (DRMA) stake by 2,779% in Q1 2026, buying an estimated $57.8K and bringing the position to 35,608 shares worth $43.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7464.

UBS Group first reported a position in DRMA in Q1 2022 and has held it in 15 quarters since. The position peaked at $75.9K in Q1 2025. 7 funds tracked by Wall St. Rank hold DRMA as of Q1 2026.

  • UBS Group held 35,608 shares of Dermata Therapeutics worth $43.1K as of Q1 2026.
  • UBS Group bought 34,371 Dermata Therapeutics shares in Q1 2026, an estimated $57.8K.
  • Dermata Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7464 holding.
  • UBS Group first reported a position in Dermata Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • UBS Group's Dermata Therapeutics position peaked at $75.9K in Q1 2025.
  • 7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.